(thirdQuint)A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H.

 Pylori Positive Patients.

 This is a double blind, randomized, active controlled, phase 3 study.

 Subjects will be randomly assigned to one of the two treatment groups (CJ-12420 50mg, lansoprazole 30mg).

 All subjects will be asked to take 5 tablets include clarithromycin, amoxicillin twice a day for 7 days.

 After the treatment, UBT test will be conducted to confirm the Helicobacter pylori eradication.

.

 A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H.

 Pylori Positive Patients@highlight

The current study is designed to demonstrate the non-inferiority of CJ-12420-based triple therapy (CJ-12420, amoxicillin and clarithromycin) versus lansoprazole-based triple therapy (lansoprazole, amoxicillin and clarithromycin) in H.

 pylori eradication rate and to evaluate the safety of CJ-12420 following oral administration of either triple therapy twice daily for 7 days in H.

 pylori positive patients.

